Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Frailty in Heart Failure: Insights, Patient Outcomes & Future Directions
Author(s): Karol Mirkowski , Ercole Vellone , Bernadetta Żółkowska , et al Added: 8 months ago

Heart Failure
THT 25: The RELIEVE-HF Study
Author(s): Gregg Stone Added: 9 months ago
THT Conference 2025 - Outcomes after heart failure patients were treated with an interatrial shunt show heart failure with reduced ejection fraction (HFrEF) patients had further benefit compared to heart failure with preserved ejection fraction (HFpEF) patients. The study's prediction model revealed four independent predictors of two-year adverse outcomes in HFrEF patients treated with medical… View more

Heart Failure
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF
Author(s): Barry Borlaug Added: 1 month ago
HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.The SUMMIT… View more

Cardiovascular Renal Metabolic

Heart Failure
EuroPCR 25: The TRINITY Trial
Author(s): Thomas Modine Added: 5 months ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement… View more

Heart Failure

Intervention
Undiagnosed Sleep Apnoea Linked to Adverse Myocardial Remodelling in Hypertrophic Cardiomyopathy
Added: 2 months ago Source:  Radcliffe Cardiology
Sleep-disordered breathing (SDB), a condition mediated by intermittent hypoxaemia and autonomic dysregulation, is a well-established contributor to cardiovascular morbidity. A new prospective cohort study suggests that patients with hypertrophic cardiomyopathy (HCM) are particularly at risk, revealing a high prevalence of previously undiagnosed SDB in this population. The research links the… View more

Heart Failure

Imaging & Diagnostics
AHA 2025: The TIRZSEMA-CVOT Study
Author(s): Nils Krüger Added: 5 days ago
AHA Scientific Sessions 2025 - Dr Nils Krüger (Brigham and Women's Hospital, US) joins us to discuss findings from the TIRZSEMA-CVOT (NCT07096063) study, examining real-world cardiovascular outcomes with tirzepatide and semaglutide in patients with type 2 diabetes at cardiovascular risk.This retrospective cohort study utilized three national US claims databases to evaluate over 887,000 patients… View more

Cardiovascular Renal Metabolic

Heart Failure
Guideline-directed Medical Therapy is the Most Effective Decongestion
Author(s): Jelena Celutkiene , Alexandre Mebazaa , Jan Biegus , et al Added: 9 months ago

Heart Failure
AHA 25: The FOOD-HF Trial
Author(s): Ambarish Pandey Added: 4 days ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents findings from a randomized clinical trial comparing medically tailored meals versus produce supplements on heart failure readmissions and emergency department visits.The study was conducted across two centers in Dallas, Texas. Patients were randomized within two weeks following heart… View more

Heart Failure

Prevention & Chronic Conditions
ADA 24: FLOW Trial: Kidney Outcomes in Patients Treated with Semaglutide
Author(s): Vlado Perkovic Added: 1 year ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 8 months ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions